TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAKTIC study aimed at exploring the combination of paclitaxel and LY2780301 in this population.

Source: European Journal of Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Keyvan Rezai, Magali Provansal, Jos é Adélaïde, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Cornel Popovici, Emmanuelle Charafe-Jauffret, Max Chaf Tags: Original Research Source Type: research